A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

Tasisulam sodium (hereafter referred to as tasisulam) is a novel, highly albumin‐bound agent that demonstrated activity in a phase 2 melanoma study.

[1]  H. Kluger,et al.  Immunotherapy for metastatic melanoma , 2012, Journal of cellular biochemistry.

[2]  P. LoRusso,et al.  A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors , 2012, Cancer Chemotherapy and Pharmacology.

[3]  J. Kirkwood,et al.  A phase 2 study of tasisulam sodium (LY573636 sodium) as second‐line treatment for patients with unresectable or metastatic melanoma , 2011, Cancer.

[4]  G. Evans,et al.  Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization , 2011, Molecular Cancer Therapeutics.

[5]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[6]  C. Slapak,et al.  A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[7]  D. Alwis,et al.  286 Tailored dosing of tasisulam-sodium (LY573636-sodium) to reduce hematologic toxicity and improve therapeutic index , 2010 .

[8]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[9]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[10]  A. Hauschild,et al.  Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Hauschild,et al.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Gonzalez,et al.  2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM) , 2008 .

[13]  Theresa Smith,et al.  Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma , 2004, Melanoma research.

[14]  D. Trump,et al.  A phase II study of taxol in patients with malignant melanoma , 1991, Investigational New Drugs.

[15]  A. Hauschild,et al.  Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG) , 2003, Melanoma research.

[16]  Cancer Therapy Evaluation Program.  Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[17]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[18]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[19]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Hainsworth,et al.  One-hour paclitaxel infusions: review of safety and efficacy. , 1999, The cancer journal from Scientific American.

[21]  A. Einzig,et al.  Taxol in malignant melanoma. , 1993, Journal of the National Cancer Institute. Monographs.

[22]  J. Burroughs,et al.  Overview of Taxol safety. , 1993, Journal of the National Cancer Institute. Monographs.

[23]  R. Benjamin,et al.  A phase II trial of taxol in metastatic melanoma , 1990, Cancer.

[24]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[25]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[26]  E. Krementz,et al.  Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A) , 1984, Cancer.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .